Currently, multispiral computed tomography of coronary arteries (MSCT) is the most informative method for diagnosing subclinical CHD, as well as in symptomatic patients (gold standard method). Investigators are interested in including all patients who have undergone coronary artery MSCT within the last year, who will be divided into groups:
1. Those with no cardiac pain at baseline and the diagnosis of CHD was not established before MSCT and was not confirmed by the MSCT result. Patients without any pain syndrome.
2. Those with initial cardiac pain considered as atypical angina pectoris but IBS not confirmed by MSCT.
3. Those in whom the initial cardiac pain was considered as atypical angina and the diagnosis of CHD was confirmed by MSCT.
4. Those in whom the diagnosis of CHD was verified before MSCT and confirmed by MSCT.
According to the results of MSCT, all included will be divided into a group without CHD and two groups with CHD:
1. \- without clinical manifestations of CHD with low calcium score and without plaques (without signs of CHD)
2. \- without clinical manifestations of CHD with high calcium count, presence of plaques and without stenosis (subclinical CHD)
3. -with clinical manifestations of CHD with high calcium count, plaques and stenoses of different degrees (clinical CHD).
Accordingly, the differences of Raman spectrum in these groups will be revealed, which will make it possible to determine the degree of coronary atherosclerosis severity and stratify cardiovascular risk with a certain accuracy based only on the blood serum spectrum. These data will undoubtedly be of high scientific and practical value. To our knowledge, no similar studies have been conducted in the world.
No additional invasive procedures are anticipated in this study. A single blood draw is performed from the catheter before contrast injection for MSCT using a certified technique.
Aim: To propose a technology for early diagnosis of CHD and cardiovascular risk stratification based on serum metabolic shifts determined by serum Raman spectroscopy.
Objectives:
1. To study the features of Surface Enhanced Raman spectrum ( SERS) depending on belonging to 1)group without CHD; 2)group with subclinical CHD; 3)group with CHD.
2. To determine the possibility of reliable division of patients into these groups using the model based on SERS and SERS model in combination with known clinical parameters using artificial intelligence methodology.
3. To propose a model of CHD risk stratification based on the obtained data.
